{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-074164","form_type":"8-K","ticker":"UNCY","cik":"0001766140","company_name":"Unicycive Therapeutics, Inc.","filed_at":"2023-09-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.160459+00:00","generated_at":"2026-06-10T23:31:02.782586+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Unicycive Therapeutics appoints veteran drug developer Sara Kenkare-Mitra to board","bullets":["Appointed Sara Kenkare-Mitra, PhD as independent director effective September 6, 2023.","Dr. Kenkare-Mitra is President & Head of R&D at Alector; previously 23 years at Genentech as SVP.","She played key role in >100 IND/CTA filings and 11 drug approvals across multiple diseases.","Her expertise expected to help advance oxylanthanum carbonate toward NDA filing and UNI-494 IND."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-074164","json":"https://secwatch.observer/filing/0001213900-23-074164.json","markdown":"https://secwatch.observer/filing/0001213900-23-074164.md","text":"https://secwatch.observer/filing/0001213900-23-074164.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1766140/000121390023074164/0001213900-23-074164-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1766140/000121390023074164/ea184727-8k_unicycive.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T23:31:02.782586+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a89b84df51","claim":"Sara Kenkare-Mitra was appointed as Independent Director at Unicycive Therapeutics, Inc..","evidence_excerpt":"On September 5, 2023, Unicycive Therapeutics, Inc. (the “Company”) appointed Sara Kenkare-Mitra as an independent director.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390023074164/0001213900-23-074164-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Independent Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}